Loading clinical trials...

Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study | Clinical Trials | Clareo Health

COMPLETED

Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study

Xamiol® Gel in BODY Psoriasis : lonG-term Management of Psoriasis vUlgARis With Xamiol® Gel in Daily Clinical Practice of Russian Dermatologists. A Long-term Observational, Prospective Study

NCT02636101•LEO Pharma

View on ClinicalTrials.gov

Summary

This study aims to describe the patient population treated and the real-life patients' experiences with Xamiol®gel in the long term, up to 52 weeks management of body psoriasis vulgaris in Russia. The result will increase the knowledge on Xamiol®gel enabling dermatologists and patients to optimize its use in the long term management of psoriasis.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Psoriasis vulgaris on body
•Patients planned to receive topical treatment on the body with calcipotriol/betamethasone gel
•Written informed consent

Exclusion Criteria

•No or very mild symptoms of psoriasis vulgaris on the body at study start
•Any on-going treatments at study start with topical steroids, salicylic acid or its combination
•Other topical treatment for body psoriasis
•Pregnancy or planned pregnancy within treatment period
•Contraindications according to prescribing information.

Locations (1)

Municipal out-patient clinic 7

Saratov, Russia

Key Dates

Start Date

January 1, 2016

Primary Completion Date

February 15, 2018

Completion Date

February 15, 2018

Last Updated

December 13, 2019

Enrollment

603

ACTUAL participants

Conditions

Psoriasis Vulgaris

Interventions

Calcipotriol/betamethasone dipropionate gel

DRUG

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

NCT04080635

Psoriasis Vulgaris

View study

COMPLETEDPHASE4

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

NCT04340076

PsoriasisPsoriasis Vulgaris

View study

WITHDRAWNNA

Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 13, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study

Inclusion Criteria

Exclusion Criteria

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris

Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

A Pilot Study to Explore the Role of Gut Flora in Psoriasis

The Mediterranean Diet and Time-Restricted Eating Dietary Interventions for Psoriasis Study